Evidence map›Paper›PMID 29487219›Full record

Trial reportThe oncologist2018

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.

Xiao X Wei, Adam P Siegel, Rahul Aggarwal, Amy M Lin, Terence W Friedlander, Lawrence Fong, Won Kim, Mirela Louttit, Emily Chang, Li Zhang and 1 more

Open access · bronzeAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The oncologist, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Xiao X WeiDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA xiaox_wei@dfci.harvard.edu.
Adam P SiegelDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Rahul AggarwalDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Amy M LinDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Terence W FriedlanderDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Lawrence FongDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Won KimDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Mirela LouttitDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Emily ChangDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Li ZhangDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
Charles J RyanDivision of Hematology/Oncology, University of California, San Francisco, San Francisco, California, USA.
University of California, San Francisco · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

lessons learnedIn abiraterone- and/or enzalutamide-refractory metastatic castration-resistant prostate cancer (mCRPC) patients, selinexor led to prostate-specific antigen and/or radiographic responses in a subset of patients, indicating clinical activity in this indication.Despite twice-a-week dosing and maximal symptomatic management, selinexor was associated with significant anorexia, nausea, and fatigue in mCRPC patients refractory to second-generation anti-androgen therapies, limiting further clinical development in this patient population.This study highlights the challenge of primary endpoint selection for phase II studies in the post-abiraterone and/or post-enzalutamide mCRPC space.

backgroundSelinexor is a first-in-class selective inhibitor of nuclear export compound that specifically inhibits the nuclear export protein Exportin-1 (XPO-1), leading to nuclear accumulation of tumor suppressor proteins.

methodsThis phase II study evaluated the efficacy and tolerability of selinexor in patients with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone and/or enzalutamide.

resultsFourteen patients were enrolled. Selinexor was initially administered at 65 mg/m

conclusionSelinexor demonstrated clinical activity and poor tolerability in mCRPC patients refractory to second-line anti-androgenic agents.

Indexed as

AgedAndrostenesBenzamidesHumansHydrazinesMaleMiddle AgedNitrilesPhenylthiohydantoinProstatic Neoplasms, Castration-ResistantTriazolesabirateroneAndrostenesBenzamidesenzalutamideHydrazinesNitrilesPhenylthiohydantoinselinexorTriazoles

Identifiers

PMID29487219
PMCPMC6067936
OpenAlexW2788392735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.